Merck and Orna Therapeutics collaborate to advance Orna’s nextgen RNA technology

Collaboration supports multiple discovery efforts, including vaccines

HERTHENA-Lung02 Phase 3 trial of Patritumab Deruxtecan initiated in patients with EGFR-mutated metastatic non-small cell lung cancer

Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.

Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA

The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.

LYNPARZA approved in the EU as adjuvant treatment for early breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients

Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study

The NTM-001 Phase I clinical study is expected to be completed by the end of 2022

Ascentage Pharma and Tanner Pharma Group initiate a global innovative named Patient Program

Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.

DS-7300 Phase 2 Trial Initiated in Patients with Pretreated ExtensiveStage Small Cell Lung Cancer

DS-7300 is a specifically designed potential first-in-class B7-H3 directed antibody drug conjugate

Merck updates on Phase 3 Keynote-412 trial in advanced head and neck squamous cell carcinoma

Novavax statement on EMA Nuvaxovid label update related to allergic reaction

Novavax’ clinical development program reported no severe allergic reactions

CEPI funds consortium led by CPI to advance Caltech’s new all-in-one coronavirus vaccine

Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.